EUCTR2017-004854-41-ES进行中（未招募）1 期
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema following Large Hemispheric Infarction - CHARM
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 680
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.A clinical diagnosis of acute ischemic stroke in the middle cerebral artery (MCA) territory
- •2.A large hemispheric infarction defined as; lesion volume of 80 to 300 centimeters cubed (cm^3) on magnetic resonance imaging (MRI) diffusion-weighted imaging (DWI), or computed tomography perfusion (CTP), or an Alberta Stroke Program Early CT Score (ASPECTS) of 1 to 5 with involvement of at least 2 defined cortical regions
- •3. Screening National Institutes of Health Stroke Scale (NIHSS) >=10
- •4. Study treatment infusion within 10 hours after time of symptom onset, if known, or the time last known normal
- •5. For participants who receive thrombectomy, inclusion into the study must be based on post-thrombectomy MRI-DWI
- •NOTE: Other protocol defined Inclusion criteria may apply
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 102
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 578
排除标准
- •1.Participant is likely to have supportive care withdrawn on the first day
- •2.Commitment to decompressive craniectomy (DC) prior to enrollment
- •3.Evidence of concurrent infarction in the contralateral hemisphere sufficiently serious so as to affect functional outcome
- •NOTE: Other protocol defined Exclusion criteria may apply
研究者
相似试验
进行中（未招募）
2 期
Multi-centre, phase II/III adaptive clinical trial to assess safety and immunogenicity of Gam-COVID-Vac combined vector vaccineCTRI/2020/11/029234Human Vaccine LLC
进行中（未招募）
1 期
Study to Evaluate the Effect of continuous infusion of Tafoxiparin to treat Primary Slow Progress of Labor including prolonged latent phase and Primary Labor ArrestPrimary Slow Progress of Labor including prolonged latent phase and Primary Labor ArrestMedDRA version: 19.1 Level: LLT Classification code 10023539 Term: Labor abnormal System Organ Class: 100000004868EUCTR2016-002118-40-SEDilafor AB360
进行中（未招募）
1 期
Study to Evaluate the Effect of continuous infusion of Tafoxiparin to treat Primary Slow Progress of Labor including prolonged latent phase and Primary Labor ArrestEUCTR2016-002118-40-DKDilafor AB360
招募中
不适用
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 12-Month Trial of Leuco methylthioninium bis (hydromethanesulfonate) in Subjects with Mild to Moderate Alzheimer's DiseaseDiseases of the nervous systemKCT0001134TauRx Therapeutics88
进行中（未招募）
不适用
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in the Treatment of Ankylosing Spondylitis (AS) - START - Spondylitis Trial of Apremilast for better Rheumatic TherapyAnkylosing SpondylitisEUCTR2008-004229-40-GBImperial College London